Skip to main content
NCBI home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1992 Dec;46(6):577–581. doi: 10.1136/jech.46.6.577

Effect of subject age on costs of screening for colorectal cancer.

D K Whynes 1, A R Walker 1, J D Hardcastle 1
PMCID: PMC1059672  PMID: 1494071

Abstract

STUDY OBJECTIVE--The aim was to estimate costs and yields of faecal occult blood screening and rescreening for colorectal cancer, for differing age cohorts. DESIGN--Cost and clinical data were used as the basis for modelling the expected costs, and cost savings, resulting from the treatment of screen detected cancers, as compared with cancers detected by symptomatic presentation. SETTING--Data were derived from the MRC screening trial currently in progress in Nottingham. PARTICIPANTS--Approximately 140,000 subjects, age 50-79 years, were randomly allocated to a test (screened) and a control (unscreened) group. MAIN RESULTS--The net costs of detecting and treating a cancer following colorectal screening fall as the age of the target population increases, owing principally to the increasing incidence of the disease with age. Generally, the marginal detection and treatment costs falls for all age groups with the first screening round, but rises considerably with the second. If allowance is made for cancers prevented as a result of early detection and excision of adenomas, the costs of screening are substantially reduced for all age groups. CONCLUSIONS--Assuming a cost per QALY (quality adjusted life year gained) equivalent to that derived for the breast cancer screening programme, and a QALY gain from colorectal screening of one year, three screens, each separated by two years, appear economically justified for populations aged 60 years and above. Expected gains from cancer prevention make two screens justifiable for those between 45 and 59 years of age.

Full text

PDF
577

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blades C. A., Culyer A. J., Walker A. Health service efficiency: appraising the appraisers--a critical review of economic appraisal in practice. Soc Sci Med. 1987;25(5):461–472. doi: 10.1016/0277-9536(87)90169-9. [DOI] [PubMed] [Google Scholar]
  2. Cubbon J. The principle of QALY maximisation as the basis for allocating health care resources. J Med Ethics. 1991 Dec;17(4):181–184. doi: 10.1136/jme.17.4.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eddy D. M., Hasselblad V., McGivney W., Hendee W. The value of mammography screening in women under age 50 years. JAMA. 1988 Mar 11;259(10):1512–1519. [PubMed] [Google Scholar]
  4. Eddy D. M., Nugent F. W., Eddy J. F., Coller J., Gilbertsen V., Gottlieb L. S., Rice R., Sherlock P., Winawer S. Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology. 1987 Mar;92(3):682–692. doi: 10.1016/0016-5085(87)90018-7. [DOI] [PubMed] [Google Scholar]
  5. Eddy D. M. Screening for colorectal cancer. Ann Intern Med. 1990 Sep 1;113(5):373–384. doi: 10.7326/0003-4819-113-5-373. [DOI] [PubMed] [Google Scholar]
  6. Harris J. QALYfying the value of life. J Med Ethics. 1987 Sep;13(3):117–123. doi: 10.1136/jme.13.3.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Harris J. Unprincipled QALYs: a response to Cubbon. J Med Ethics. 1991 Dec;17(4):185–188. doi: 10.1136/jme.17.4.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kewenter J., Björk S., Haglind E., Smith L., Svanvik J., Ahrén C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer. 1988 Aug 1;62(3):645–651. doi: 10.1002/1097-0142(19880801)62:3<645::aid-cncr2820620333>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  9. Kronborg O., Fenger C., Olsen J., Bech K., Søndergaard O. Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol. 1989 Jun;24(5):599–606. doi: 10.3109/00365528909093096. [DOI] [PubMed] [Google Scholar]
  10. Kronborg O., Fenger C., Søndergaard O., Pedersen K. M., Olsen J. Initial mass screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen in Denmark. Scand J Gastroenterol. 1987 Aug;22(6):677–686. doi: 10.3109/00365528709011142. [DOI] [PubMed] [Google Scholar]
  11. Lewis A. A., Khoury G. A. Resection for colorectal cancer in the very old: are the risks too high? Br Med J (Clin Res Ed) 1988 Feb 13;296(6620):459–461. doi: 10.1136/bmj.296.6620.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Macrae F. A., St John D. J. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology. 1982 May;82(5 Pt 1):891–898. [PubMed] [Google Scholar]
  13. Multicentre randomised clinical trial of chorion villus sampling and amniocentesis. First report. Canadian Collaborative CVS-Amniocentesis Clinical Trial Group. Lancet. 1989 Jan 7;1(8628):1–6. [PubMed] [Google Scholar]
  14. Muto T., Bussey H. J., Morson B. C. The evolution of cancer of the colon and rectum. Cancer. 1975 Dec;36(6):2251–2270. doi: 10.1002/cncr.2820360944. [DOI] [PubMed] [Google Scholar]
  15. Rawles J. Castigating QALYs. J Med Ethics. 1989 Sep;15(3):143–147. doi: 10.1136/jme.15.3.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rozen P., Ron E. A cost analysis of screening methodology for family members of colorectal cancer patients. Am J Gastroenterol. 1989 Dec;84(12):1548–1551. [PubMed] [Google Scholar]
  17. Smith A. Qualms about QALYs. Lancet. 1987 May 16;1(8542):1134–1136. doi: 10.1016/s0140-6736(87)91685-0. [DOI] [PubMed] [Google Scholar]
  18. Stower M. J., Hardcastle J. D. The results of 1115 patients with colorectal cancer treated over an 8-year period in a single hospital. Eur J Surg Oncol. 1985 Jun;11(2):119–123. [PubMed] [Google Scholar]
  19. Stryker S. J., Wolff B. G., Culp C. E., Libbe S. D., Ilstrup D. M., MacCarty R. L. Natural history of untreated colonic polyps. Gastroenterology. 1987 Nov;93(5):1009–1013. doi: 10.1016/0016-5085(87)90563-4. [DOI] [PubMed] [Google Scholar]
  20. Tuck J., Walker A., Whynes D. K., Pye G., Hardcastle J. D., Chamberlain J. Screening and the costs of treating colorectal cancer: some preliminary results. Public Health. 1989 Nov;103(6):413–419. doi: 10.1016/s0033-3506(89)80050-2. [DOI] [PubMed] [Google Scholar]
  21. Umpleby H. C., Bristol J. B., Rainey J. B., Williamson R. C. Survival of 727 patients with single carcinomas of the large bowel. Dis Colon Rectum. 1984 Dec;27(12):803–810. doi: 10.1007/BF02553944. [DOI] [PubMed] [Google Scholar]
  22. Walker A. R., Whynes D. K., Hardcastle J. D. Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer. An economic perspective. Scand J Gastroenterol. 1991 Feb;26(2):215–218. doi: 10.3109/00365529109025033. [DOI] [PubMed] [Google Scholar]
  23. Walker A., Whynes D. K., Chamberlain J. O., Hardcastle J. D. The cost of screening for colorectal cancer. J Epidemiol Community Health. 1991 Sep;45(3):220–224. doi: 10.1136/jech.45.3.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Walker A., Whynes D. K. Filtering strategies in mass population screening for colorectal cancer: an economic evaluation. Med Decis Making. 1992 Jan-Mar;12(1):2–7. doi: 10.1177/0272989X9201200102. [DOI] [PubMed] [Google Scholar]
  25. Whynes D. K., Walker A. R., Hardcastle J. D. Cost savings in mass population screening for colorectal cancer resulting from the early detection and excision of adenomas. Health Econ. 1992 Apr;1(1):53–60. doi: 10.1002/hec.4730010108. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES